$MRK News Article - Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ?1)
https://marketwirenews.com/news-releases/merc...44134.html